logo

Genmab A/S (GMXAY.PK)



Trade GMXAY.PK now with
  Date
  Headline
12/13/2019 6:34:48 AM Genmab: CHMP Of EMA Issued Positive Opinion Recommending Broadening Existing Marketing Authorization For DARZALEX
8/30/2019 1:28:01 AM Genmab Says Partner Novartis Reported Positive Results For Ofatumumab
8/22/2019 1:30:14 AM Genmab Reports Approval Of DARZALEX In Frontline Multiple Myeloma In Japan
7/9/2019 6:25:06 AM Genmab Begins Public Offering Of ADSs In US
6/11/2019 1:55:44 AM Genmab Enters Exclusive License, Option Agreement With Janssen Biotech
4/3/2019 7:35:41 AM Genmab Announces Phase III Study Exploring Daratumumab As Maintenance Treatment In Newly Diagnosed Multiple Myeloma
2/12/2019 1:25:03 AM Genmab A/S: FDA Approves Split Dosing Regimen For DARZALEX
1/31/2019 3:58:00 PM MorphoSys Reports Settlement In Patent Lawsuit With Janssen And Genmab
1/26/2019 12:09:31 PM Genmab Announces That Patents Asserted Against DARZALEX In U.S. Have Been Declared Invalid By Summary Judgment
1/22/2019 6:50:13 AM Genmab: Net Sales Of DARZALEX In 2018 Total $2.025 Bln
10/29/2018 4:54:29 PM Genmab Reports Positive Topline Results In Phase III MAIA Study Of Daratumumab In Front Line Multiple Myeloma
10/16/2018 6:48:29 AM Genmab A/S Q3 Worldwide Net Sales Of DARZALEX As Reported By Johnson & Johnson $498 Mln
8/31/2018 8:36:07 AM Genmab Announces European Marketing Authorization For DARZALEX For Front Line Multiple Myeloma
8/8/2018 11:04:21 AM Genmab H1 Operating Income DKK 459 Mln Vs. DKK 582 Mln Prior Year
  
 
>